Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CCEL 
CryoCell International Inc (CCEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: CCEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.5
1 Year Target Price $8.5
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 22.98% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 41.21M USD | Price to earnings Ratio 509.9 | 1Y Target Price 8.5 |
Price to earnings Ratio 509.9 | 1Y Target Price 8.5 | ||
Volume (30-day avg) 1 | Beta 0.74 | 52 Weeks Range 4.61 - 8.62 | Updated Date 07/2/2025 |
52 Weeks Range 4.61 - 8.62 | Updated Date 07/2/2025 | ||
Dividends yield (FY) 11.56% | Basic EPS (TTM) 0.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.4% | Operating Margin (TTM) 13.25% |
Management Effectiveness
Return on Assets (TTM) 3.99% | Return on Equity (TTM) 129.2% |
Valuation
Trailing PE 509.9 | Forward PE - | Enterprise Value 51357847 | Price to Sales(TTM) 1.28 |
Enterprise Value 51357847 | Price to Sales(TTM) 1.28 | ||
Enterprise Value to Revenue 1.6 | Enterprise Value to EBITDA 8.78 | Shares Outstanding 8082160 | Shares Floating 4425790 |
Shares Outstanding 8082160 | Shares Floating 4425790 | ||
Percent Insiders 40.17 | Percent Institutions 12.75 |
Upturn AI SWOT
CryoCell International Inc
Company Overview
History and Background
CryoCell International Inc. was founded in 1989. They pioneered private umbilical cord blood banking, giving families the option to preserve stem cells from their newborn for potential future medical use. Over time, they have expanded services, including cord tissue banking and genetic testing.
Core Business Areas
- Cord Blood Banking: Collection and cryogenic storage of umbilical cord blood, rich in hematopoietic stem cells, for potential future transplantation needs.
- Cord Tissue Banking: Collection and cryogenic storage of umbilical cord tissue, rich in mesenchymal stem cells, for potential regenerative medicine applications.
- Genetic Testing: Offer a range of genetic tests, including newborn screening and carrier screening, to provide insights into a child's health risks and predispositions.
Leadership and Structure
CryoCell is led by its executive team, including a CEO, CFO, and other key functional heads. Organizational structure is typically departmentalized with dedicated teams for sales, marketing, laboratory operations, and customer service.
Top Products and Market Share
Key Offerings
- Cord Blood Banking: The flagship service. Provides long-term storage of cord blood stem cells. Market share estimated around 25-30% in the private cord blood banking sector. Key competitors: CBR (Cord Blood Registry), ViaCord, Americord. Revenue is difficult to determine precisely but represents the majority of CryoCell's revenue stream.
- Cord Tissue Banking: Storage of umbilical cord tissue stem cells. Growing market with less defined market share data. Competitors: CBR, ViaCord, Americord.
- Genetic Testing: Offers various genetic tests. Market share is smaller compared to core banking services, competing with larger genetic testing companies.
Market Dynamics
Industry Overview
The cord blood banking industry is a specialized healthcare segment focused on the collection, processing, and cryopreservation of stem cells derived from umbilical cord blood and tissue. It's driven by awareness of stem cell therapies and regenerative medicine.
Positioning
CryoCell is positioned as an established and reputable provider in the private cord blood banking market. Competitive advantages include its long history and focus on quality and customer service.
Total Addressable Market (TAM)
The global cord blood banking market is projected to reach several billion dollars. CryoCell's positioning enables it to capture a significant portion of this TAM through its established brand and service offerings.
Upturn SWOT Analysis
Strengths
- Established brand reputation
- Pioneering experience in the industry
- Strong customer service
- Comprehensive service offerings (blood and tissue)
Weaknesses
- High customer acquisition costs
- Market sensitivity to economic downturns
- Regulatory complexities
- Limited geographic presence (primarily US)
Opportunities
- Expansion of genetic testing services
- Partnerships with hospitals and healthcare providers
- Geographic expansion into international markets
- Increased awareness of stem cell therapies
Threats
- Competition from larger cord blood banks
- Changing regulations and industry standards
- Public cord blood banks offering free services
- Advancements in alternative stem cell sources
Competitors and Market Share
Key Competitors
- CBR
- ViaCord
- Americord
Competitive Landscape
CryoCell is a prominent player but faces competition from larger companies with greater resources. Differentiation through quality, customer service, and expanding service offerings is crucial.
Major Acquisitions
Russo International, Inc.
- Year: 2021
- Acquisition Price (USD millions): 1.1
- Strategic Rationale: To expand and diversify service offerings in reproductive tissue storage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends would be assessed based on revenue and customer acquisition data from past years - requires retrieval of the financial reports which I do not have access to.
Future Projections: Future growth projections are based on market trends, analyst estimates, and company strategies - requires retrieval of the financial reports which I do not have access to.
Recent Initiatives: Information of the recent strategic initiatives undertaken by the CryoCell.
Summary
CryoCell International is an established player in the private cord blood banking industry with a solid reputation. While the company faces strong competition and regulatory hurdles, its focus on quality and expansion into related services like genetic testing provide growth opportunities. Maintaining customer trust and adapting to evolving technologies are crucial for sustained success. The expansion into reproductive tissue storage, may give CryoCell an edge over its competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Press releases
- Financial databases
Disclaimers:
This analysis is based on publicly available information and analyst estimates. Actual results may vary. The AI-based rating is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CryoCell International Inc
Exchange NYSE MKT | Headquaters Oldsmar, FL, United States | ||
IPO Launch date 1997-01-21 | Chairman & Co-CEO Mr. David I. Portnoy | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 82 | Website https://www.cryo-cell.com |
Full time employees 82 | Website https://www.cryo-cell.com | ||
Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells, which are used in regenerative medicine to treat a range of conditions. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.